{
    "doi": "https://doi.org/10.1182/blood.V120.21.1639.1639",
    "article_title": "Rituximab, Bendamustine, Mitoxantrone, Dexamethasone (R-BMD) in Patients with Follicular Lymphoma in Relapse or Refractory to First-Line Treatment with Immunochemotherapy. R-BMD Geltamo 08 Trial ",
    "article_date": "November 16, 2012",
    "session_type": "624. Lymphoma - Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster I",
    "abstract_text": "Abstract 1639 Objectives To evaluate the efficacy and safety of rituximab-bendamustine-mitoxantrone-dexamethasone (R-BMD) in patients with relapsed or refractory follicular lymphoma, (R/R FL) to first-line therapy with R-chemotherapy (R-ChemoT), followed by maintenance with R. Methods Phase II trial including 61 patients with R/R LF, after a 1 st R-ChemoT line. Induction treatment: Rituximab 375 mg/m 2 iv, day 1; bendamustine 90 mg/m 2 iv, days 1 and 2; mitoxantrone 6 mg/m 2 /day iv, day 1; oral dexamethasone 20 mg / day, days 1 to 5. Cycles of 28 days. Evaluation of response after 3 rd cycle. If stable disease or progression: withdrawal from the study. If complete response (CR) or complete response unconfirmed (CRu): administration of a 4 th cycle. If partial response (PR): administration up to 6 cycles. If CR, CRu or PR at the end of induction: patients receive maintenance with R 375 mg/m 2 /day every 12 weeks for 2 years. Primary objective: Complete responses (CR + CRu). Results are presented as valid % and median [range]. Results Results from 46 patients who completed induction period. 52.2% women, age 63 [32\u201376] years. Ann Arbor stage III / IV 75.6% (31/41) and III / IV-B 22.6% (7/31). FLIPI: intermediate risk 28.9% (11/38); high-risk 23.7% (9/38). Number of administered cycles: 4 [1\u20136]. Overall response 93.5% (43/46); CR: see Table 1 . Progression Free Survival \u2013median (CI95%)-: 14.5 (11.6-NA) months. The most relevant grade 3/4 toxicity: neutropenia 52% (n = 24; 17 patients received G-CSF) and thrombocytopenia 4.3% (n = 2). Infections grade 3/4: 6.5% (n = 3). One patient died due to CMV reactivation. No skin reactions were reported. There are maintenance available data from 15 patients: 3 patients sustained CR at the end of this period, and 2 patients progressed. Conclusions R-BMD is a treatment schedule effective and a safe alternative for patients with R/R FL, after a 1st line with R-ChemoT. No skin reactions were reported, possibly due to the inclusion of dexamethasone in the treatment scheme. Additional follow up is required to achieve more conclusive findings. Table 1. Response after R-BMD induction in patients with R/R FL after 1 st line with R-ChemoT  Response after 3 rd cycle . Better response after induction . . N (%) . CI 95% . . N (%) . CI 95% . CR/CRu 27 (60,0) [44,3\u201374,3] CR/CRnc 33 (73,3) [58,1\u201385,4] PR 15 (33,3) [20,0\u201349,0] PR 10 (22,2) [11,2\u201337,1] SD 2 (4,4) [0,5\u201315,2] SD 2 (4,4) [0,5\u201315,2] Unknown *  1 (2,2) [0,1\u201311,8]    Total ^  45 (100)  Total ^  45 (100)  Response after 3 rd cycle . Better response after induction . . N (%) . CI 95% . . N (%) . CI 95% . CR/CRu 27 (60,0) [44,3\u201374,3] CR/CRnc 33 (73,3) [58,1\u201385,4] PR 15 (33,3) [20,0\u201349,0] PR 10 (22,2) [11,2\u201337,1] SD 2 (4,4) [0,5\u201315,2] SD 2 (4,4) [0,5\u201315,2] Unknown *  1 (2,2) [0,1\u201311,8]    Total ^  45 (100)  Total ^  45 (100)  * Patients without evaluation after the 3 rd cycle. He received an additional cycle and was evaluated after end of induction. ^ One non evaluable patient. View Large Disclosures: No relevant conflicts of interest to declare.",
    "topics": [
        "bendamustine",
        "dexamethasone",
        "follicular lymphoma",
        "mitoxantrone",
        "rituximab",
        "complete remission",
        "chemotherapy regimen",
        "cmv reactivation",
        "follow-up",
        "granulocyte colony-stimulating factor"
    ],
    "author_names": [
        "Francisco Javier Pen\u0303alver",
        "Jose\u0301 Antonio Ma\u0301rquez",
        "Soledad Dura\u0301n",
        "Pilar Giraldo",
        "Carlos Montalban",
        "Mari\u0301a Jose\u0301 Rami\u0301rez",
        "Juan Manuel Sancho",
        "Mari\u0301a Jose\u0301 Terol, MD, PhD",
        "Francisco Javier Capote",
        "Antonio Gutie\u0301rrez",
        "Blanca Sa\u0301nchez",
        "Miguel Canales",
        "Mari\u0301a Dolores Caballero"
    ],
    "author_dict_list": [
        {
            "author_name": "Francisco Javier Pen\u0303alver",
            "author_affiliations": [
                "Haematology, Hospital Universitario Fundacio\u0301n Alcorco\u0301n, Madrid, Spain, "
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Jose\u0301 Antonio Ma\u0301rquez",
            "author_affiliations": [
                "Hospital de Basurto, Vizcaya, Spain, "
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Soledad Dura\u0301n",
            "author_affiliations": [
                "Hematology, Complejo Hospitalario de Jae\u0301n, Jae\u0301n, Spain, "
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Pilar Giraldo",
            "author_affiliations": [
                "Haematology, Hospital Universitario Miguel Servet, Zaragoza, Spain, "
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Carlos Montalban",
            "author_affiliations": [
                "Internal Medicine, Hospital Universitario Ramon y Cajal, Madrid, Spain, "
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Mari\u0301a Jose\u0301 Rami\u0301rez",
            "author_affiliations": [
                "Hematology, Hospital de especialidades de Jere\u0301z de la Frontera, Jere\u0301z de la Frontera, Spain, "
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Juan Manuel Sancho",
            "author_affiliations": [
                "Hematology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain, "
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Mari\u0301a Jose\u0301 Terol, MD, PhD",
            "author_affiliations": [
                "Haematology, Hospital Cli\u0301nico Universitario de Valencia, Valencia, Spain, "
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Francisco Javier Capote",
            "author_affiliations": [
                "Hematology, Hospital Puerta del Mar, Ca\u0301diz, Spain, "
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Antonio Gutie\u0301rrez",
            "author_affiliations": [
                "Hematology, Hospital Universitario Son Dureta, Palma, Spain, "
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Blanca Sa\u0301nchez",
            "author_affiliations": [
                "Hematology, Hospital del Mar, Barcelona, Spain, "
            ],
            "author_rank": 11,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Miguel Canales",
            "author_affiliations": [
                "Hematology, Hospital Universitario La Paz, Madrid, Spain, "
            ],
            "author_rank": 12,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Mari\u0301a Dolores Caballero",
            "author_affiliations": [
                "Hematology, Hospital Universitario Salamanca, Salamanca, Spain"
            ],
            "author_rank": 13,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-05-24T02:32:17",
    "is_scraped": "1"
}